Risks and mechanisms of cardiovascular events in users of oral contraceptives
- 1 June 1988
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 158 (6) , 1646-1652
- https://doi.org/10.1016/0002-9378(88)90203-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomyThrombosis Research, 1986
- HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDYThe Lancet, 1986
- Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.BMJ, 1986
- An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasmaBritish Journal of Haematology, 1986
- A novel form of factor VII in plasma from men at risk for cardiovascular diseaseBritish Journal of Haematology, 1985
- British Pill Studies Stress Importance of Relation Between Progestogen Content and Vascular DiseaseFamily Planning Perspectives, 1980
- Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.BMJ, 1980
- HÆMOSTATIC, LIPID, AND BLOOD-PRESSURE PROFILES OF WOMEN ON ORAL CONTRACEPTIVES CONTAINING 50 µg OR 30 µg ŒSTROGENThe Lancet, 1977
- Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of DrugsBMJ, 1970
- Clotting Factors during Oral Contraception: Further ReportBMJ, 1966